ClinicalTrials.gov
ClinicalTrials.gov Menu

Development of a Family-Based Treatment for Adolescent Methamphetamine Use (AIMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00680511
Recruitment Status : Completed
First Posted : May 20, 2008
Last Update Posted : August 5, 2014
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Oregon Research Institute

Brief Summary:
The AIMS study compares a methamphetamine-specific treatment intervention to a treatment-as-usual Functional Family Therapy (FFT) approach for adolescents ages 15 to 19. Adolescents are assigned to one of two treatment conditions: (1) 16 weeks of FFT designed to strengthen family relationships and develop skills for helping the adolescent avoid drug use; or (2) 16 weeks of a combination of FFT and a methamphetamine-specific intervention involving group and individual therapy sessions; Families are assessed using questionnaires and interviews, and adolescents participate in neuropsychological testing, before, during, and after treatment to provide information about family functioning, the adolescent's drug use, the adolescent's peers, and other factors that may contribute to treatment success. Adolescents also provide urine specimens for drug screening at assessment visits. Through a partnership with Oregon Health and Science University (OHSU), adolescents will participate in functional magnetic resonance imaging appointments at the hospital to examine regional brain blood flow during tasks designed to measure impulsivity and risk-taking behaviors. As a treatment development grant, study investigators will study adolescents' acceptance of and response to the newly developed methamphetamine-specific treatment approach.

Condition or disease Intervention/treatment Phase
Behavior and Mental Disorders Methamphetamine Disorders Behavioral: Adolescent Methamphetamine Treament (AMT) Behavioral: Functional Family Therapy (FFT) Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Development of a Family-Based Treatment for Adolescent Methamphetamine Use
Study Start Date : September 2007
Actual Primary Completion Date : September 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Methamphetamine
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1
Family therapy combined with methamphetamine-specific group treatment.
Behavioral: Adolescent Methamphetamine Treament (AMT)
AMT Group Therapy plus Functional Family Therapy (FFT)
Active Comparator: 2
Family Therapy.
Behavioral: Functional Family Therapy (FFT)
FFT



Primary Outcome Measures :
  1. Substance Use [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Engagement and retention of adolescent methamphetamine users. [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 19 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 15 to 19 years of age.
  • Have at least one parent or parent figure willing to participate.
  • Meet DSM-IV diagnostic criteria for drug-abuse or dependence, including a specific meth use disorder.
  • Reports meth use on at least 5 of the previous 90 days.
  • Have contact with the parent on at least 40% of the past 90 days.
  • With their parent be willing to accept randomization to one of the two treatment interventions.
  • Be willing to participate in the imaging task in the fMRI pilot study.
  • Have basic English competency.
  • Have sufficient residential stability to permit probable contact at follow-up.

Exclusion Criteria:

  • Evidence of psychotic or organic state of sufficient severity to interfere with understanding of study instruments and procedures.
  • Have a medical or psychological condition that would preclude undergoing the fMRI scan.
  • Have a sibling who is participating in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00680511


Locations
United States, Oregon
Oregon Research Institute Center for Family and Adolescent Research
Portland, Oregon, United States, 97205
Sponsors and Collaborators
Oregon Research Institute
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Holly B. Waldron, Ph.D. Oregon Research Institute

Additional Information:
Responsible Party: Oregon Research Institute
ClinicalTrials.gov Identifier: NCT00680511     History of Changes
Other Study ID Numbers: DA021695
First Posted: May 20, 2008    Key Record Dates
Last Update Posted: August 5, 2014
Last Verified: August 2014

Keywords provided by Oregon Research Institute:
methamphetamine abuse

Additional relevant MeSH terms:
Disease
Mental Disorders
Psychotic Disorders
Pathologic Processes
Schizophrenia Spectrum and Other Psychotic Disorders
Methamphetamine
Central Nervous System Stimulants
Physiological Effects of Drugs
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors